Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

ESSA Pharma Announces Initiation Of Phase 2 Study Evaluating Masofaniten (EPI-7386) In Combination with Enzalutamide In Patients with Metastatic Castration-Resistant Prostate Cancer

Author: Benzinga Newsdesk | September 18, 2023 07:02am

Posted In: EPIX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist